Annual report pursuant to Section 13 and 15(d)

Segments (Details) - Schedule of business segments primarily based on revenues and net

v3.23.1
Segments (Details) - Schedule of business segments primarily based on revenues and net - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenues    
Total revenues $ 486,559 $ 15,062
Net loss    
Total net loss (13,936,452) (2,173,521)
Therapeutics [Member]    
Revenues    
Total revenues
Clinics1 [Member]    
Revenues    
Total revenues 486,559 15,062
Drug Research and Development [Member]    
Net loss    
Total net loss (11,727,885) (1,908,925)
Clinics2 [Member]    
Net loss    
Total net loss $ (2,208,567) $ (264,596)